Freenome Joins Liquid Biopsy Cancer Detection Race with Whole-Genome Machine Learning …

NEW YORK (GenomeWeb) – Freenome, another new entrant to the circulating tumor DNA analysis market, said last week that it has raised $5.5 million in seed funding to support commercialization of its technology. Unlike current liquid biopsy tests on the market or in development, Freenome’s testing will be based on genome-wide sequencing and a computational strategy the firm calls an “Adaptive Genomics Engine” (AGE). Get the full story withGenomeWeb Premium Only $95 for thefirst 90 days* A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story. Try GenomeWeb Premium now. Already a GenomeWeb Premium member? Login Now.Or, See if your institution qualifies for premium access. *Before your trial expires, we’ll put together a custom quote…


Link to Full Article: Freenome Joins Liquid Biopsy Cancer Detection Race with Whole-Genome Machine Learning …